

Phosphodiesterase type 5 as a pharmacologic target in e

Urology

60, 4-11

DOI: 10.1016/s0090-4295(02)01686-2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sildenafil: A 4-year update in the treatment of 20 million erectile dysfunction patients. <i>Current Urology Reports</i> , 2003, 4, 488-496.	1.0	34
2	Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. <i>European Journal of Pharmacology</i> , 2003, 477, 163-169.	1.7	46
3	1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2341-2345.	1.0	28
4	Isolation of two isoforms of phosphodiesterase 5 from rat penis. <i>International Journal of Impotence Research</i> , 2003, 15, 129-136.	1.0	18
5	What is the relevance of bioinformatics to pharmacology?. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 434-439.	4.0	45
6	Androgens and Cardiovascular Disease. <i>Endocrine Reviews</i> , 2003, 24, 313-340.	8.9	647
7	Localized Effects of cAMP Mediated by Distinct Routes of Protein Kinase A. <i>Physiological Reviews</i> , 2004, 84, 137-167.	13.1	665
8	A 66-Year-Old Man With Sexual Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2994.	3.8	27
9	Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>New England Journal of Medicine</i> , 2004, 350, 552-559.	13.9	541
10	Novel nitric oxide signaling mechanisms regulate the erectile response. <i>International Journal of Impotence Research</i> , 2004, 16, S15-S19.	1.0	125
11	Differential inhibitor sensitivity between human recombinant and native photoreceptor cGMP-phosphodiesterases (PDE6s). <i>Biochemical Pharmacology</i> , 2004, 68, 867-873.	2.0	18
12	Causes of Erectile Dysfunction. <i>Endocrine</i> , 2004, 23, 119-124.	2.2	20
13	Phosphodiesterase-5 inhibitors: Clinical market and basic science comparative studies. <i>Current Urology Reports</i> , 2004, 5, 451-459.	1.0	8
15	The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. <i>Respiratory Research</i> , 2004, 5, 4.	1.4	24
16	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. <i>EAU Update Series</i> , 2004, 2, 56-63.	0.5	19
17	Therapeutic interventions targeting the nitric oxide system: Current and potential uses in obstetrics, bone disease and erectile dysfunction. <i>Life Sciences</i> , 2004, 74, 1701-1721.	2.0	8
18	DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. <i>Life Sciences</i> , 2004, 75, 1075-1083.	2.0	8
19	Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats. <i>Journal of Ethnopharmacology</i> , 2004, 94, 85-92.	2.0	36

#	ARTICLE	IF	CITATIONS
20	Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. <i>Biochemical Journal</i> , 2004, 380, 371-384.	1.7	24
21	Cyclic nucleotide signaling in vascular and cavernous smooth muscle: aging-related changes. <i>Advances in Cell Aging and Gerontology</i> , 2004, 16, 57-106.	0.1	1
22	Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. <i>Biochemical Journal</i> , 2005, 388, 803-811.	1.7	135
23	The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1653.	3.8	1,324
24	Past, present, and future: a 7-year update of Viagra® (sildenafil citrate). <i>International Journal of Clinical Practice</i> , 2005, 59, 680-691.	0.8	70
25	Peroxynitrite-induced relaxation in isolated rat aortic rings and mechanisms of action. <i>Toxicology and Applied Pharmacology</i> , 2005, 209, 269-276.	1.3	50
26	Nitric oxide and penile erectile function. , 2005, 106, 233-266.		185
27	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. <i>Vascular Pharmacology</i> , 2005, 42, 219-232.	1.0	184
28	Effect of berberine on the mRNA expression of nitric oxide synthase (NOS) in rat corpus cavernosum. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2005, 25, 127-130.	1.0	9
29	Urologic Diseases in Elderly Men. <i>Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association</i> , 2005, 48, 236.	0.1	2
30	Regulation of intracellular Ca <sup>2+</sup> release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. <i>American Journal of Physiology - Cell Physiology</i> , 2005, 288, C650-C658.	2.1	39
31	Structural Determinants for Inhibitor Specificity and Selectivity in PDE2A Using the Wheat Germ in Vitro Translation System. <i>Biochemistry</i> , 2005, 44, 8312-8325.	1.2	62
32	IMPROVING ERECTILE FUNCTION BY SILENCING PHOSPHODIESTERASE-5. <i>Journal of Urology</i> , 2005, 174, 1142-1148.	0.2	27
33	Aging in the Hypothalamic-Pituitary-Testicular Axis. , 2006, , 2697-2728.		5
34	Phosphodiesterase-5 Isoforms: Differential Cyclic Guanyl Monophosphate Binding and Cyclic Guanyl Monophosphate Catalytic Activities, and Inhibitory Effects of Sildenafil and Vardenafil. <i>Journal of Urology</i> , 2006, 176, 1242-1247.	0.2	3
35	Evaluation and Medical Management of Erectile Dysfunction. <i>Mayo Clinic Proceedings</i> , 2006, 81, 385-390.	1.4	24
36	The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy. <i>Journal of Clinical Hypertension</i> , 2006, 8, 53-62.	1.0	137
37	Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat. <i>Life Sciences</i> , 2006, 78, 1211-1216.	2.0	13

#	ARTICLE	IF	CITATIONS
38	The nitric oxide-guanosine 3',5'-cyclic monophosphate pathway regulates dopamine efflux in the medial preoptic area and copulation in male rats. <i>Neuroscience</i> , 2006, 139, 417-428.	1.1	24
39	Synthesis, radiolabeling and in vivo evaluation of [11C]RAL-01, a potential phosphodiesterase 5 radioligand. <i>Nuclear Medicine and Biology</i> , 2006, 33, 593-597.	0.3	33
41	Cardiovascular and metabolic effects of natriuretic peptides. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 41-49.	1.0	23
42	Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. <i>International Journal of Impotence Research</i> , 2006, 18, 251-257.	1.0	17
43	Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in penile cavernosum. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2006, 26, 460-462.	1.0	17
44	Sildenafil for pulmonary arterial hypertension. <i>Future Cardiology</i> , 2006, 2, 137-143.	0.5	2
45	The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 437-454.	1.0	68
46	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. <i>International Journal of Impotence Research</i> , 2007, 19, 139-148.	1.0	49
47	PDE5 inhibitors beyond erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007, 19, 533-543.	1.0	67
48	Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor. <i>Life Sciences</i> , 2007, 80, 699-708.	2.0	7
49	Molecular modeling studies of pyridopurinone derivatives-Potential phosphodiesterase 5 inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 378-390.	1.3	44
50	Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. <i>Journal of Physiology</i> , 2007, 584, 137-147.	1.3	16
51	Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum. <i>British Journal of Pharmacology</i> , 2007, 150, 353-360.	2.7	14
52	Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. <i>British Journal of Pharmacology</i> , 2007, 152, 1102-1110.	2.7	40
53	Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2007, 137, 181-192.	1.2	130
54	Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1247-1253.	2.8	19
55	Nonurologic applications of phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , 2007, 4, 64-70.	0.4	2
56	Extraction and DNA digestion of 5'-phosphodiesterase from malt root. <i>Tsinghua Science and Technology</i> , 2008, 13, 480-484.	4.1	9

#	ARTICLE	IF	CITATIONS
57	Real-time monitoring of phosphodiesterase inhibition in intact cells. <i>Cellular Signalling</i> , 2008, 20, 1423-1431.	1.7	47
58	Combination of Alfuzosin and Tadalafil Exerts In Vitro an Additive Relaxant Effect on Human Corpus Cavernosum. <i>Journal of Sexual Medicine</i> , 2008, 5, 935-945.	0.3	24
59	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2008, 5, 1841-1865.	0.3	124
60	Essential role of mitochondrial Ca <sup>2+</sup> -activated and ATP-sensitive K <sup>+</sup> channels in sildenafil-induced late cardioprotection. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 105-113.	0.9	71
61	Functional Chimeras of the Phosphodiesterase 5 and 10 Tandem GAF Domains. <i>Journal of Biological Chemistry</i> , 2008, 283, 25164-25170.	1.6	11
62	Sexual dysfunction: the "prima ballerina"™ of hypertension-related quality-of-life complications. <i>Journal of Hypertension</i> , 2008, 26, 2074-2084.	0.3	113
63	Discovery of the nitric oxide signaling pathway and targets for drug development. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 1.	3.0	195
64	Combination of Doxazosin and Sildenafil Exerts an Additive Relaxing Effect Compared with Each Compound Alone on Human Cavernosal and Prostatic Tissue. <i>Journal of Sexual Medicine</i> , 2009, 6, 836-847.	0.3	39
65	Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil. <i>Journal of Sexual Medicine</i> , 2009, 6, 2039-2048.	0.3	58
66	The effects of sildenafil on the functional and structural changes of ileum induced by intestinal ischemia"reperfusion in rats. <i>European Journal of Pharmacology</i> , 2009, 610, 87-92.	1.7	19
67	Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. <i>Radiologia Medica</i> , 2009, 114, 1106-1114.	4.7	42
68	The effect of sildenafil, a phosphodiesterase"5 inhibitor, on acetic acid-induced colonic inflammation in the rat. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1142-1148.	1.4	34
69	A Novel Access to Arylated and Heteroarylated Beta-Carboline Based PDE5 Inhibitors. <i>Medicinal Chemistry</i> , 2010, 6, 374-387.	0.7	5
70	Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 1029-1037.	1.2	10
71	Ginsenoside Rg1 Improves Male Copulatory Behavior Via Nitric Oxide/Cyclic Guanosine Monophosphate Pathway. <i>Journal of Sexual Medicine</i> , 2010, 7, 743-750.	0.3	43
72	Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. <i>British Journal of Pharmacology</i> , 2010, 160, 1135-1143.	2.7	68
73	Modulation of penile erection in rabbits by <i>mondia whitei</i> : possible mechanism of action. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2010, 7, 241-52.	0.3	11
74	Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010, 298, R433-R438.	0.9	24

#	ARTICLE	IF	CITATIONS
75	Phosphodiesterase-5 inhibition by sildenafil citrate in a rat model of bleomycin-induced lung fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2010, 23, 215-221.	1.1	41
76	The effect of phosphodiesterase-5 inhibition by sildenafil citrate on inflammation and apoptosis in rat experimental colitis. <i>Life Sciences</i> , 2011, 89, 402-407.	2.0	29
77	<i>Kaempferia parviflora</i> , a plant used in traditional medicine to enhance sexual performance contains large amounts of low affinity PDE5 inhibitors. <i>Journal of Ethnopharmacology</i> , 2011, 137, 1437-1441.	2.0	43
78	Phosphodiesterases as Targets for Modulating T-Cell Responses. <i>Handbook of Experimental Pharmacology</i> , 2011, , 345-363.	0.9	31
79	Sexuality in psychosis: dysfunction, risk and mental capacity. <i>Advances in Psychiatric Treatment</i> , 2011, 17, 275-282.	0.6	4
80	Sildenafil treatment attenuates lung and kidney injury due to overproduction of oxidant activity in a rat model of sepsis: a biochemical and histopathological study. <i>Clinical and Experimental Immunology</i> , 2011, 166, 374-384.	1.1	59
81	Erectogenic Effects of <i>Clerodendron capitatum</i> : Involvement of Phosphodiesterase Type-5 Inhibition. <i>Evidence-based Complementary and Alternative Medicine</i> , 2012, 2012, 1-6.	0.5	1
82	Novel therapeutic targets for erectile dysfunction. <i>Maturitas</i> , 2012, 71, 20-27.	1.0	16
83	Simultaneous screening and determination of 18 illegal adulterants in herbal medicines and health foods for male sexual potency by ultrafast liquid chromatography-electrospray ionization tandem mass spectrometry. <i>Journal of Separation Science</i> , 2012, 35, 2847-2857.	1.3	32
84	Acute Effects of Sildenafil on Uroflowmetric Parameters in Erectile Dysfunction Patients With and Without Lower Urinary Tract Symptoms. <i>Journal of Andrology</i> , 2012, 33, 1165-1168.	2.0	4
85	<i>Mondia whitei</i> , a Medicinal Plant from Africa with Aphrodisiac and Antidepressant Properties: A Review. <i>Journal of Dietary Supplements</i> , 2012, 9, 272-284.	1.4	25
86	South African plants and male reproductive healthcare: Conception and contraception. <i>Journal of Ethnopharmacology</i> , 2012, 143, 475-480.	2.0	38
87	Tadalafil. <i>Drugs and Aging</i> , 2012, 29, 771-781.	1.3	9
88	Phosphodiesterase Inhibitors, Congestive Heart Failure, and Sudden Death: Time for Reevaluation. <i>Congestive Heart Failure</i> , 2012, 18, 229-233.	2.0	19
89	Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 805-811.	1.4	17
90	Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice. <i>Molecular Immunology</i> , 2013, 56, 649-659.	1.0	21
91	Contemporary management of erectile dysfunction. <i>Urological Science</i> , 2013, 24, 35-40.	0.2	3
92	<i>Panax notoginseng</i> saponins improve the erectile dysfunction in diabetic rats by protecting the endothelial function of the penile corpus cavernosum. <i>International Journal of Impotence Research</i> , 2013, 25, 206-211.	1.0	19

#	ARTICLE	IF	CITATIONS
93	Daily Dosing of PDE5 Inhibitors: Where Does it Fit in?. <i>Current Urology Reports</i> , 2013, 14, 269-278.	1.0	7
94	Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2013, 30, 2027-2034.	1.1	29
95	Physiology of Erection. , 2014, , 1-12.		0
96	Androgen Dependent Penile Development and Erection Physiologyâ€”A Molecular Connection?. <i>Journal of Urology</i> , 2014, 192, 8-9.	0.2	0
97	Editorial Comment to Extracorporeal shockwave therapy in the treatment of erectile dysfunction: A prospective, randomized, double-blind, placebo controlled study. <i>International Journal of Urology</i> , 2014, 21, 1045-1045.	0.5	0
98	Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2015, 49, 358-362.	0.4	15
99	The evaluation of penile microvascular endothelial function using laser speckle contrast imaging in healthy volunteers. <i>Microvascular Research</i> , 2015, 99, 96-101.	1.1	6
100	Object memory enhancement by combining sub-eficacious doses of specific phosphodiesterase inhibitors. <i>Neuropharmacology</i> , 2015, 95, 361-366.	2.0	35
101	Ultrasound up-regulates expression of heme oxygenase-1 gene in endothelial cells. <i>Journal of Medical Ultrasonics (2001)</i> , 2015, 42, 467-475.	0.6	6
102	Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 689-698.	0.6	9
103	Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action. <i>International Journal of Impotence Research</i> , 2016, 28, 20-24.	1.0	10
104	Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 311-330.	2.5	26
105	Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. <i>ChemMedChem</i> , 2017, 12, 487-501.	1.6	151
106	Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 675-683.	1.2	6
107	Structural investigation of vesnarinone at the pore domains of open and open-inactivated states of hERG1 K <sup>+</sup> channel. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 77, 399-412.	1.3	6
108	Phosphodiesterase 5 Inhibitors from <i>Derris scandens</i> . <i>Planta Medica</i> , 2018, 84, 1134-1140.	0.7	5
109	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Menâ€”2017. <i>Journal of Sexual Medicine</i> , 2018, 15, 430-457.	0.3	91
110	<i>Kaempferia parviflora</i> ethanol extract improves self-assessed sexual health in men: a pilot study. <i>Journal of Integrative Medicine</i> , 2018, 16, 249-254.	1.4	18

#	ARTICLE	IF	CITATIONS
111	Alkaloid extracts from Bitter leaf ( <i>Vernonia amygdalina</i> ) and Black nightshade ( <i>Solanum</i> ) Tj ETQqO 0 0 rgBT /Overlock 10 Tf Journal of Food Biochemistry, 2019, 43, e12889.	1.2	8
112	In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors. <i>Scientia Pharmaceutica</i> , 2019, 87, 29.	0.7	1
113	Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil. <i>Chemical Biology and Drug Design</i> , 2019, 93, 419-429.	1.5	6
114	<i>Pfaffia glomerata</i> hydroalcoholic extract stimulates penile tissue in adult Swiss mice. <i>Journal of Ethnopharmacology</i> , 2020, 261, 113182.	2.0	14
115	Toxicology of natural and synthetic aphrodisiacs. <i>Rechtsmedizin</i> , 2020, 30, 15-30.	2.6	7
116	Fluorescence polarisation for high-throughput screening of adulterated food products via phosphodiesterase 5 inhibition assay. <i>Drug Testing and Analysis</i> , 2021, 13, 953-964.	1.6	4
117	Changes in the Pharmacokinetics and Pharmacodynamics of Sildenafil in Cigarette and Cannabis Smokers. <i>Pharmaceutics</i> , 2021, 13, 876.	2.0	7
118	Exploration of the effect of pulmonary fibrosis on erectile function in rats: A study based on bioinformatics and experimental research. <i>Andrologia</i> , 2021, 53, e14085.	1.0	1
119	Inhibition of ABCC5-mediated cGMP transport by progesterone, testosterone and their analogues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 213, 105951.	1.2	0
120	Influence of Energy Drinks on Pharmacokinetic Parameters of Sildenafil in Rats. <i>Biomedical and Pharmacology Journal</i> , 2018, 11, 1317-1328.	0.2	2
121	The role of cGMP as a mediator of lipolysis in bovine oocytes and its effects on embryo development and cryopreservation. <i>PLoS ONE</i> , 2018, 13, e0191023.	1.1	9
122	Misoprostol and the Sildenafil analog (PHAR-0099048) Modulate Cellular Efflux of cAMP and cGMP Differently. <i>Pharmacology &amp; Pharmacy</i> , 2013, 04, 104-109.	0.2	8
123	<i>SexualitÄt.</i> , 2004, , 259-298.		0
124	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. , 2004, , 35-47.		0
125	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. , 2004, , 129-142.		0
127	<i>Phosphodiesterase 6.</i> , 2007, , 1-16.		0
128	Haemolysis in PNH: Depletion of Nitric Oxide. , 2017, , 121-135.		0
129	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , 2011, 16, e30-5.	1.3	40



#	ARTICLE	IF	CITATIONS
131	Knowledge, Attitude, Confidence, and Barriers in the Practice of Erectile Dysfunction Screening among Primary Health-Care Providers in Taiping Perak, Malaysia. <i>Urological Science</i> , 2019, 30, 170-176.	0.2	0
132	Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure. <i>Life Sciences</i> , 2022, 289, 120237.	2.0	3
133	Sildenafil (Viagra) Aggravates the Development of Experimental Abdominal Aortic Aneurysm. <i>Journal of the American Heart Association</i> , 2022, 11, e023053.	1.6	9
135	In vitro inhibition of phosphodiesterase type 4 enhances rat corpus cavernosum nerve-mediated relaxation induced by gasotransmitters. <i>Life Sciences</i> , 2022, 296, 120432.	2.0	3
136	Update on Treatment Options for Stuttering Priapism. <i>Current Sexual Health Reports</i> , 2022, 14, 140-149.	0.4	1